{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "increases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uaz:UAZ00399",
      "entity_text" : "EQ-5D-3L",
      "entity_type" : "protein"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "pfam:PF02512",
      "entity_text" : "UK",
      "entity_type" : "family"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "For instance, in a recent assessment of a novel therapy in end stage renal disease, the UK National Institute for Health & Care Excellence (NICE) had accepted the EQ-5D-3L based utilities in a cost-utility model [XREF_BIBR].",
  "reading_complete" : "2020-08-02T13:25:00Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-02T13:23:07Z",
  "trigger" : "accepted",
  "evidence" : [ "UK National Institute for Health & Care Excellence (NICE) had accepted the EQ-5D-3L" ],
  "pmc_id" : "6615078",
  "score" : 0
}